AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2011
May 18, 2011
29864_dirs_2011-05-18_b0600c75-4a6e-4411-bcd6-d909eac665d5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2011-05-16
Reporting Person: MUELLER PETER (EVP, Global R&D, CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-05-16 | Common Stock | M | 2500 | $10.41 | Acquired | 136235 | Direct |
| 2011-05-16 | Common Stock | S | 100 | $55.44 | Disposed | 136135 | Direct |
| 2011-05-16 | Common Stock | S | 700 | $56.79 | Disposed | 135435 | Direct |
| 2011-05-16 | Common Stock | S | 1700 | $57.21 | Disposed | 133735 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-05-16 | Stock Options | $10.41 | M | 2500 | Disposed | 2015-02-02 | Common Stock (2500) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4495 | Indirect |
Footnotes
F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $56.79 (range $56.61 to $56.92).
F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $57.21 (range $57.00 to $57.49).
F5: Fully vested.